Author:
Al-Sabri Mohamed H.,Ammar Nourhane,Korzh Stanislava,Alsehli Ahmed M.,Hosseini Kimia,Fredriksson Robert,Mwinyi Jessica,Williams Michael J.,Boukhatmi Hadi,Schiöth Helgi B.
Abstract
AbstractPreviously, we showed that fluvastatin treatment induces myofibrillar damage and mitochondrial phenotypes in the skeletal muscles of Drosophila. However, the sequential occurrence of mitochondrial phenotypes and myofibril damage remains elusive. To address this, we treated flies with fluvastatin for two and five days and examined their thorax flight muscles using confocal microscopy. In the two-day fluvastatin group, compared to the control, thorax flight muscles exhibited mitochondrial morphological changes, including fragmentation, rounding up and reduced content, while myofibrils remained organized in parallel. In the five-day fluvastatin treatment, not only did mitochondrial morphological changes become more pronounced, but myofibrils became severely disorganized with significantly increased thickness and spacing, along with myofilament abnormalities, suggesting myofibril damage. These findings suggest that fluvastatin-induced mitochondrial changes precede myofibril damage. Moreover, in the five-day fluvastatin group, the mitochondria demonstrated elevated H2O2 and impaired fatty acid oxidation compared to the control group, indicating potential mitochondrial dysfunction. Surprisingly, knocking down Hmgcr (Drosophila homolog of HMGCR) showed normal mitochondrial respiration in all parameters compared to controls or five-day fluvastatin treatment, which suggests that fluvastatin-induced mitochondrial dysfunction might be independent of Hmgcr inhibition. These results provide insights into the sequential occurrence of mitochondria and myofibril damage in statin-induced myopathy for future studies.
Funder
Vetenskapsrådet
AFM-Telethon trampoline grant
ATIP-Avenir
Uppsala University
Publisher
Springer Science and Business Media LLC
Reference69 articles.
1. Peters, S. A. E., Singhateh, Y., Mackay, D., Huxley, R. R. & Woodward, M. Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: A systematic review and meta-analysis. Atherosclerosis 248, 123–131 (2016).
2. Deaths from cardiovascular disease surged 60% globally over the last 30 years: Report. World Heart Federation https://world-heart-federation.org/news/deaths-from-cardiovascular-disease-surged-60-globally-over-the-last-30-years-report/.
3. Goldstein, J. L. & Brown, M. S. Regulation of the mevalonate pathway. Nature 343, 425–430 (1990).
4. Baigent, C. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010).
5. Musunuru, K. Treating coronary artery disease: Beyond statins, ezetimibe, and PCSK9 inhibition. Ann. Rev. Med. 72, 447–458 (2021).